[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631914":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":11,"locations":18,"responsibleParty":75,"collaborators":11,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":11,"eligibilityCriteria":84,"healthyVolunteers":81,"sex":85,"minAge":86,"maxAge":11,"enrollmentInfo":87,"targetDuration":11,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":11,"overallStatus":21,"whyStopped":11,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Legacy Health System","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Concurrent endocrine therapy with the chemotherapy and HER2 directed therapy","EXPERIMENTAL",null,[13],"Drug: Concurrent endocrine therapy with the chemotherapy and HER2 directed therapy",[15],{"type":16,"name":9,"description":9,"armGroupLabels":17,"otherNames":11},"DRUG",[9],[19,39,52,63],{"facility":20,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"Legacy Mount Hood Medical Center","RECRUITING","Gresham","Oregon","97030","United States","US",{"type":28,"coordinates":29},"Point",[30,31],-122.43148,45.49818,{"lat":31,"lon":30},[34],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":38},"Legacy Oncology Clinical Research","CONTACT","503-13-8199","oncologyresearch@lhs.org",{"facility":40,"status":21,"city":41,"state":23,"zip":42,"country":25,"countryCode":26,"cosmosGeoPoint":43,"geoPoint":47,"contacts":48},"Legacy Good Samaritan Medical Center","Portland","97210",{"type":28,"coordinates":44},[45,46],-122.67621,45.52345,{"lat":46,"lon":45},[49],{"name":50,"role":36,"phone":51,"phoneExt":11,"email":38},"Legacy Oncology Research","503-413-8199",{"facility":53,"status":21,"city":54,"state":23,"zip":55,"country":25,"countryCode":26,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Legacy Meridian Park Medical Center","Tualatin","97062",{"type":28,"coordinates":57},[58,59],-122.76399,45.38401,{"lat":59,"lon":58},[62],{"name":35,"role":36,"phone":51,"phoneExt":11,"email":38},{"facility":64,"status":21,"city":65,"state":66,"zip":67,"country":25,"countryCode":26,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Legacy Salmon Creek Medical Center","Vancouver","Washington","98686",{"type":28,"coordinates":69},[70,71],-122.66149,45.63873,{"lat":71,"lon":70},[74],{"name":35,"role":36,"phone":51,"phoneExt":11,"email":38},{"type":76,"investigatorFullName":77,"investigatorTitle":78,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Nathalie Johnson","Principal Investigator","100631914","phase-2-concurrent-neoadjuvant-chemoendocrine-therapy-in-her2-breast-cancer-100631914",false,"NCT07506876","Concurrent Neoadjuvant Chemo\u002FEndocrine Therapy in HER2+ Breast Cancer","Inclusion Criteria:\n\n1. Adults over 18 years of age with newly diagnosed, previously untreated, HR+, HER2+ breast cancer (positive per local guidelines)\n\n   1. Endocrine therapy for the current breast cancer may be started within 28 days prior to trial enrollment and must be initiated prior to C2 of chemotherapy\u002FHER2 directed therapy\n   2. Choice of endocrine therapy will be determined by the treating and\u002For enrolling physician\n2. Anatomic Stage IIA - IIIC breast cancer planning a minimum of 4 cycles of TCHP\n3. Patients must be Luminal A, Luminal B or HER2 enriched subtype on MammaPrint\u002FBluePrint performed on initial biopsy\n\nExclusion Criteria:\n\n1. Children under 18 years of age, pregnant women, prisoners, and decisionally impaired adults.\n2. Patients with non-breast cancer within prior 2 years\n3. Patients with breast cancer within prior 5 years\n4. Patients with recurrent breast cancer\n5. Patients with stage IV breast cancer","ALL","18 Years",{"count":88,"type":89},30,"ESTIMATED","INTERVENTIONAL",[92],"PHASE2","The usual approach to care for hormone receptor positive, HER2 positive breast cancer is chemotherapy and HER2 targeted therapy followed by endocrine therapy and surgery.\n\nThe purpose of this Research Study is to see if taking endocrine therapy with the chemotherapy and HER2 directed therapy increases patients response to therapy at the time of surgery",[95,96],"Breast Cancer - Infiltrating Ductal Carcinoma","HER-2 Positive Breast Cancer","2026-04-27",{"date":99,"type":100},"2026-05-01","ACTUAL",{"date":97,"type":100},{"date":103,"type":89},"2027-12",{"name":5,"class":6},4]